Psychosomatic Medicine Faster Service from Outside North America
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Herrmann-Lingen, C.
Right arrow Articles by Pieske, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Herrmann-Lingen, C.
Right arrow Articles by Pieske, B.
Related Collections
Right arrow Other Cardiovascular Medicine
Right arrow Neuroendocrine
Right arrow Anxiety
Right arrow Psychophysiology
Psychosomatic Medicine 65:517-522 (2003)
© 2003 American Psychosomatic Society


ORIGINAL ARTICLES

High Plasma Levels of N-Terminal Pro-Atrial Natriuretic Peptide Associated With Low Anxiety in Severe Heart Failure

Christoph Herrmann-Lingen, MD, Lutz Binder, MD, Michael Klinge, MS, Julia Sander, MS, Wiebke Schenker, MS, Beate Beyermann, MD, Dirk von Lewinski, MD and Burkert Pieske, MD

From the Departments of Psychosomatics and Psychotherapy (C.HL., M.K.), Cardiology (B.B., D.VL., B.P.), and Clinical Chemistry (L.B., J.S., W.S.), University of Göttingen, Göttingen, Germany.

Address reprint requests to: Christoph Herrmann-Lingen, MD, Department of Psychosomatics and Psychotherapy, University of Göttingen, von-Siebold-Strasse 5, D-37075 Göttingen, Germany. Email: cherrma{at}gwdg.de

Received for publication May 10, 2002; revision received August 7, 2002.

OBJECTIVE: Plasma levels of natriuretic peptides are elevated in congestive heart failure (CHF). These peptides show anxiolytic properties in studies of rodents and patients with panic disorder, but their possible effect on anxiety has never been studied in cardiac patients. We therefore assessed associations of the Atrial Natriuretic Pro-Peptide (pro-ANP) with anxiety in patients with CHF and controls.

METHOD: This was a cross-sectional study of 119 patients (46 with CHF, 76 controls with cardiovascular risk factors) in a tertiary care center. The study included assessment of CHF severity, ejection fraction, pro-ANP (microtiter assay), and psychosocial status (self-rating questionnaires for anxiety, depression, vital exhaustion, and quality of life).

RESULTS: The diagnosis and severity of CHF was significantly related to pro-ANP levels, bad physical quality of life, vital exhaustion, and depression. However, there was no significant effect of disease severity on anxiety. In CHF patients, pro-ANP was negatively correlated with anxiety ({rho} = -0.30, p = .041). In the whole group, anxiety was independently predicted by vital exhaustion, depression, and younger age (overall adjusted R2 = 0.48). Pro-ANP plasma levels showed an additional, inverse association with anxiety (ß = -0.17, p = .013, adjusted R2 = 0.50). Predicted mean anxiety scores derived from this model showed a good fit with anxiety scores observed in subgroups defined by CHF severity.

CONCLUSION: Pro-ANP plasma levels are independently and inversely related to anxiety. Even in severe CHF with severely compromised quality of life, anxiety tends to decrease with high pro-ANP levels. This might be part of a negative feedback loop limiting psychological distress and its adverse autonomic consequences in severe heart failure.

Key Words: Pro-ANP, • congestive heart failure, • anxiety.

Abbreviations: ANOVA = analysis of variance;; ANP = atrial natriuretic peptide;; CHF = congestive heart failure;; HADS = Hospital Anxiety and Depression Scale;; LVEF = left ventricular ejection fraction;; MQ = Maastricht Questionnaire;; NYHA = New York Heart Association;; pro-ANP = N-terminal Pro-Atrial Natriuretic Peptide;; PTCA = percutaneous transluminal coronary angioplasty;; QoL = quality of life;; SF36 = Short Form 36 Health Survey.




This article has been cited by other articles:


Home page
HeartHome page
J T Parissis, M Nikolaou, D Farmakis, V Bistola, I A Paraskevaidis, S Adamopoulos, G Filippatos, and D T Kremastinos
Clinical and prognostic implications of self-rating depression scales and plasma B-type natriuretic peptide in hospitalised patients with chronic heart failure
Heart, May 1, 2008; 94(5): 585 - 589.
[Abstract] [Full Text] [PDF]


Home page
Psychology of MusicHome page
P. Lin, J. Chang, V. Zemon, and E. Midlarsky
Silent illumination: a study on Chan (Zen) meditation, anxiety, and musical performance quality
Psychology of Music, April 1, 2008; 36(2): 139 - 155.
[Abstract] [PDF]


Home page
Alcohol AlcoholHome page
T. Hillemacher and S. Bleich
Neurobiology and Treatment in Alcoholism--Recent Findings Regarding Lesch's Typology of Alcohol Dependence
Alcohol Alcohol., March 13, 2008; (2008) agn016v1.
[Abstract] [Full Text] [PDF]


Home page
Alcohol AlcoholHome page
T. HILLEMACHER, K. BAYERLEIN, J. WILHELM, D. POLEO, H. FRIELING, M. ZIEGENBEIN, W. SPERLING, J. KORNHUBER, and S. BLEICH
VOLUME INTAKE AND CRAVING IN ALCOHOL WITHDRAWAL
Alcohol Alcohol., January 1, 2006; 41(1): 61 - 65.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the American Psychosomatic Society